Literature DB >> 2293206

Transdermal delivery of bioactive peptides: the effect of n-decylmethyl sulfoxide, pH, and inhibitors on enkephalin metabolism and transport.

H K Choi1, G L Flynn, G L Amidon.   

Abstract

We investigated the effects of the nonionic surfactant, n-decylmethyl sulfoxide (NDMS), pH, and inhibitors on the metabolism and the permeation of amino acids, dipeptides, and the pentapeptide enkephalin, through hairless mouse skin. An HPLC gradient method was developed to identify the possible peptide and amino acid metabolites of leucine-enkephalin. NDMS increased the permeability of all amino acids and peptides tested. At neural pH, the enzyme activity within the skin was such that no flux of leucine-enkephalin (YGGFL) was observed and the donor cell concentration of YGGFL decreased rapidly. The major cleavage occurred at the Tyr-Gly bond. At pH 5.0 the metabolic activity was reduced significantly and a substantial flux of YGGFL was observed. Enzymatically stable YGGFL analogues, Tyr-D-Ala-Gly-Phe-Leu (YDAGFL) and its amide, exhibited significant fluxes even at neutral pH in the presence of NDMS, but with substantial metabolism. YDAGFL amide was more stable to metabolism than YDAGFL. The rates of metabolism of the peptides in the skin homogenates were in the order: FL much greater than YGGFL greater than GFL greater than GGFL much greater than YG, YGG much greater than YDAGFL amide. In the skin homogenates puromycin and amastatin showed the highest inhibitory effects, while FL and GFL were only slightly active. However, in the skin diffusion experiments, FL allowed the highest amount of intact parent compound to permeate, making it the most potent inhibitor. These results show that the complex proteolytic enzyme activities occurring during skin permeation are different from those in skin homogenates and that a combination of enhancer, pH adjustment, and inhibitors can increase the transdermal delivery of peptides.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2293206     DOI: 10.1023/a:1015915922363

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  22 in total

1.  Effects of enkephalin in analogues on prolactin release in the rat.

Authors:  H Y Meltzer; R J Miller; R G Fessler; M Simonovic; V S Fang
Journal:  Life Sci       Date:  1978-06-05       Impact factor: 5.037

2.  The relationship between enkephalin degradation and opiate receptor occupancy.

Authors:  M Knight; W A Klee
Journal:  J Biol Chem       Date:  1978-06-10       Impact factor: 5.157

3.  Mode of deactivation of the enkephalins by rat and human plasma and rat brain homogenates.

Authors:  J M Hambrook; B A Morgan; M J Rance; C F Smith
Journal:  Nature       Date:  1976-08-26       Impact factor: 49.962

4.  Transdermal drug transport and metabolism. II. The role of competing kinetic events.

Authors:  R O Potts; S C McNeill; C R Desbonnet; E Wakshull
Journal:  Pharm Res       Date:  1989-02       Impact factor: 4.200

5.  Structure activity relationship of orally active enkephalin analogues as analgesics.

Authors:  D Roemer; J Pless
Journal:  Life Sci       Date:  1979-02-12       Impact factor: 5.037

6.  Inhibition of enkephalin-degrading aminopeptidase activity by certain peptides.

Authors:  R K Barclay; M A Phillipps
Journal:  Biochem Biophys Res Commun       Date:  1980-10-31       Impact factor: 3.575

Review 7.  Biological inactivation of enkephalins and the role of enkephalin-dipeptidyl-carboxypeptidase ("enkephalinase") as neuropeptidase.

Authors:  J C Schwartz; B Malfroy; S De La Baume
Journal:  Life Sci       Date:  1981-10-26       Impact factor: 5.037

8.  Inhibition of the enzymatic degradation of Leu--enkephalin by puromycin.

Authors:  R K Barclay; M A Phillips
Journal:  Biochem Biophys Res Commun       Date:  1978-04-28       Impact factor: 3.575

9.  Systemic absorption of ocularly administered enkephalinamide and inulin in the albino rabbit: extent, pathways, and vehicle effects.

Authors:  R E Stratford; L W Carson; S Dodda-Kashi; V H Lee
Journal:  J Pharm Sci       Date:  1988-10       Impact factor: 3.534

10.  Passage of somatostatin analogue across human and mouse skin.

Authors:  C J Weber; D Jicha; S Matz; J Siverly; T O'Dorisio; L Strausberg; J Laurencot; A McLarty; J Norton; M Kazim
Journal:  Surgery       Date:  1987-12       Impact factor: 3.982

View more
  4 in total

Review 1.  Chemical enhancers for transdermal drug transport.

Authors:  K Bauerová; D Matusová; Z Kassai
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Jan-Jun       Impact factor: 2.441

2.  Hydrogel-based iontotherapeutic delivery devices for transdermal delivery of peptide/protein drugs.

Authors:  A K Banga; Y W Chien
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

Review 3.  An analysis of the role of skin Langerhans cells (LC) in the cytoplasmic processing of HIV-1 peptides after "peplotion" transepidermal transfer and HLA class I presentation to CD8+ CTLs--an approach to immunization of humans.

Authors:  Y Becker
Journal:  Virus Genes       Date:  1995-01       Impact factor: 2.332

Review 4.  Ethosomal nanocarriers: the impact of constituents and formulation techniques on ethosomal properties, in vivo studies, and clinical trials.

Authors:  Ibrahim M Abdulbaqi; Yusrida Darwis; Nurzalina Abdul Karim Khan; Reem Abou Assi; Arshad A Khan
Journal:  Int J Nanomedicine       Date:  2016-05-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.